Türk Medline
ADR Yönetimi
ADR Yönetimi

FACTORS AFFECTING SURVIVAL IN HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE, OPERATED BREAST CANCER PATIENTS

GİZEM BAKİR KAHVECİ,, UMMUGUL UYETURK

Eurasian Journal of Medical Investigation - 2025;9(2):89-96

Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Türkiye

 

Objectives: The aim of this study is to investigate the effects of demographic, clinical, histopathological features and treatment on prognosis in hormone receptor positive HER-2 negative operated breast cancer patients followed up in the oncology outpatient clinic. Methods: Breast cancer patients with hormone receptor-positive, HER2-negative status who underwent surgery and presented to the medical oncology outpatient clinic between January 1, 2012, and December 31, 2018, were retrospectively evaluated. The patients’ demographic characteristics at diagnosis, tumor type, number of lymph nodes, pathological tumor stage, and Ki-67 indices were analyzed. Statistical analysis was performed using SPSS version 15.0 software.Ethical approval for the study was obtained from the Bolu Abant İzzet Baysal University Non-Interventional Clinical Research Ethics Committee (Approval Date: 27.12.2018, Decision No: 2018/280). Results: A total of 165 patients with hormone receptor-positive, HER2-negative breast cancer who underwent surgery were included in the study based on hospital data. The median age at diagnosis was 55 years (minimum 22 – maximum 85). Of the patients, 61 (37%) were premenopausal, and 104 (63%) were postmenopausal. The most common tumor type was invasive ductal carcinoma (75.2%). A statistically significant difference was observed between surviving and deceased patients regarding the number of lymph nodes (p=0.003), pathological tumor stage (p=0.004), and TNM stage (p=0.004). Additionally, the proportion of patients with Ki-67 ?20% was significantly higher in those who experienced recurrence compared to those without recurrence (p=0.002). Conclusion: Lymph node involvement and number, tumor size, hormone receptor status, and HER2 status are reliable prognostic markers. Consistent with previous studies, our findings indicate that increased tumor size, a higher number of involved lymph nodes, and elevated Ki-67 expression are associated with poorer survival outcomes.